Autres langues AbbVie Inc.

Actions

ABBV

US00287Y1091

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:56:13 18/05/2026			Varia. 5j.	Varia. 1 janv.
208,38 ^USD	-0,96%		+3,05%	-8,55%

15/05	Mubadala Investment Co PJSC renforce ses positions dans AbbVie et Match Group, s'allège sur CVS Health	RE
15/05	ABBVIE INC. : Evercore ISI persiste à l'achat	ZM

Autres langues

15/05	Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health
13/05	US FDA approves BeOne's drug for a type of blood cancer
12/05	Declaration of Voting Results by AbbVie Inc
12/05	Het Ierse fiscale succes versus het risico op afhankelijkheid
12/05	Il successo fiscale irlandese di fronte al rischio di dipendenza
11/05	Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence
11/05	Irlands Steuererfolg und das Risiko der Abhängigkeit
11/05	El éxito fiscal de Irlanda frente al riesgo de dependencia
11/05	Morning Meeting: Same old story
09/05	Ireland's fiscal success faces the risk of over-reliance
08/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance
06/05	AbbVie to Present at the Bank of America Securities Healthcare Conference
06/05	Morning Meeting: Anleger sind echte Chip-Jäger
05/05	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
05/05	AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases
04/05	Weight-loss revolution sparks new appetite for aesthetics firms
04/05	Global pharma companies that have publicly announced Trump drug pricing agreements
04/05	Kyverna Therapeutics, Inc. Appoints Nadia Dac as Chief Commercial Officer, Effective May 4, 2026
04/05	SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
04/05	Abbvie Announces Skyrizi (Risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
04/05	Tenax Therapeutics, Inc. Appoints Timothy Healey as Chief Commercial Officer, Effective May 4, 2026
01/05	Big Pharma M&A set for mega year as patent expiries drive deal urgency
30/04	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
30/04	AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says
30/04	Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month